# Alpha Cognition Inc.: overview

ACOG · Nasdaq · CIK 1655923 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/acog.md) · [Financials](/companies/acog/financials.md) · [Filings](/companies/acog/filings.md) · [Insiders](/companies/acog/insiders.md)

Latest reported revenue: [$6.1m](/filings/0001213900-26-089188.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:Revenues, accession 0001213900-26-089188).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [2.9](/filings/0001213900-26-056588.md) | [1.7](/filings/0001213900-26-089188.md) | [2.8](/filings/0001213900-25-110061.md) | [2.8 d](/filings/0001213900-26-037614.md) | [3.5](/filings/0001213900-26-056588.md) | [6.1](/filings/0001213900-26-089188.md) |
| Gross margin | % | not reported | not reported | not reported | [87.7%](/filings/0001213900-26-089188.md) | not reported | not reported | not reported | [93.6%](/filings/0001213900-26-089188.md) |
| Operating margin | % | not reported | not reported | [(116.3%)](/filings/0001213900-26-056588.md) | [(509.6%)](/filings/0001213900-26-089188.md) | [(187.0%)](/filings/0001213900-25-110061.md) | [(283.7%) d](/filings/0001213900-26-037614.md) | [(229.1%)](/filings/0001213900-26-056588.md) | [(127.3%)](/filings/0001213900-26-089188.md) |
| Net margin | % | not reported | not reported | [(58.9%)](/filings/0001213900-26-056588.md) | [(796.2%)](/filings/0001213900-26-089188.md) | [(46.4%)](/filings/0001213900-25-110061.md) | [(245.5%) d](/filings/0001213900-26-037614.md) | [(183.3%)](/filings/0001213900-26-056588.md) | [(144.3%)](/filings/0001213900-26-089188.md) |
| Diluted EPS | $ per share | [(0.31)](/filings/0001213900-25-110061.md) | not reported | [(0.11)](/filings/0001213900-26-056588.md) | [(0.82)](/filings/0001213900-26-089188.md) | [(0.30)](/filings/0001213900-25-110061.md) | not reported | [(0.32)](/filings/0001213900-26-056588.md) | [(0.40)](/filings/0001213900-26-089188.md) |
| Free cash flow | $m | not reported | not reported | [(2.1)](/filings/0001213900-26-056588.md) | [(6.1) d](/filings/0001213900-26-089188.md) | [(5.4) d](/filings/0001213900-25-110061.md) | [(7.1) d](/filings/0001213900-26-037614.md) | [(11.8)](/filings/0001213900-26-056588.md) | [(7.0) d](/filings/0001213900-26-089188.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues; Gross profit: us-gaap:GrossProfit. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [10.2](/filings/0001213900-26-037614.md) |
| Gross margin | % | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | [(221.7%)](/filings/0001213900-26-037614.md) |
| Net margin | % | not reported | not reported | [(202.2%)](/filings/0001213900-26-037614.md) |
| Diluted EPS | $ per share | [(3.84)](/filings/0001213900-25-026225.md) | [(2.04)](/filings/0001213900-26-037614.md) | [(1.18)](/filings/0001213900-26-037614.md) |
| Free cash flow | $m | not reported | [(7.8)](/filings/0001213900-26-037614.md) | [(20.7)](/filings/0001213900-26-037614.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/acog/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Opaleye Management Inc.](/funds/1595855.md) | 2026-06-30 | $20.9m | 2,895,467 |  | Added +333,517 |
| [Solas Capital Management, LLC](/funds/1604867.md) | 2026-06-30 | $13.9m | 1,924,617 |  | Unchanged |
| [AWM Investment Company, Inc.](/funds/1535264.md) | 2026-06-30 | $12.1m | 1,672,168 |  | Unchanged |
| [Cable Car Capital, LP](/funds/1699575.md) | 2026-06-30 | $10.0m | 1,382,339 |  | Unchanged |
| [Ikarian Capital, LLC](/funds/1778253.md) | 2026-06-30 | $6.0m | 836,259 |  | Reduced −220,000 |
| [SPHERA FUNDS MANAGEMENT LTD.](/funds/1496201.md) | 2026-06-30 | $3.9m | 545,816 |  | Reduced −21,800 |
| [Alyeska Investment Group, L.P.](/funds/1453072.md) | 2026-06-30 | $2.6m | 365,000 |  | Unchanged |
| [Aristides Capital LLC](/funds/1595521.md) | 2026-06-30 | $1.6m | 218,510 |  | Unchanged |
| [BOOTHBAY FUND MANAGEMENT, LLC](/funds/1549230.md) | 2026-06-30 | $1.4m | 189,148 |  | Reduced −67,245 |
| [CANTOR FITZGERALD, L. P.](/funds/1024896.md) | 2026-06-30 | $786.4k | 108,918 |  | Reduced −79,713 |

## Recent filings

[All 215 filings](/companies/acog/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-13 | 16:48 ET | [10-Q](/filings/0001213900-26-089188.md) | Quarterly report, period 2026-06-30 | 0001213900-26-089188 |
| 2026-06-23 | 10:35 ET | [8-K](/filings/0001213900-26-070903.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001213900-26-070903 |
| 2026-05-14 | 16:01 ET | [10-Q](/filings/0001213900-26-056588.md) | Quarterly report, period 2026-03-31 | 0001213900-26-056588 |
| 2026-05-01 | 16:40 ET | [8-K/A](/filings/0001213900-26-050998.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-26-050998 |
| 2026-04-30 | 16:13 ET | [DEF 14A](/filings/0001213900-26-050234.md) | Proxy statement, period 2026-06-16 | 0001213900-26-050234 |
| 2026-04-20 | 17:00 ET | [8-K](/filings/0001213900-26-045668.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-26-045668 |
| 2026-04-14 | 16:00 ET | [8-K](/filings/0001213900-26-043517.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001213900-26-043517 |
| 2026-03-31 | 17:09 ET | [10-K](/filings/0001213900-26-037614.md) | Annual report, period 2025-12-31 | 0001213900-26-037614 |
| 2026-03-27 | 17:12 ET | [8-K](/filings/0001213900-26-035696.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-035696 |
| 2026-03-26 | 16:41 ET | [8-K](/filings/0001213900-26-034778.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-034778 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-037614.md), filed Mar 31, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/5a603e81-05dd-4975-834b-d1a78b3e6636)

## About the filer

- CIK: 1655923
- Tickers: ACOG
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: A1
- Filer category: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 16:52 ET. No prices; not investment advice.